Literature DB >> 21349997

DNA repair biomarker profiling of head and neck cancer: Ku80 expression predicts locoregional failure and death following radiotherapy.

Benjamin J Moeller1, John S Yordy, Michelle D Williams, Uma Giri, Uma Raju, David P Molkentine, Lauren A Byers, John V Heymach, Michael D Story, J Jack Lee, Erich M Sturgis, Randal S Weber, Adam S Garden, K Kian Ang, David L Schwartz.   

Abstract

PURPOSE: Radiotherapy plays an integral role in the treatment of head and neck squamous cell carcinoma (HNSCC). Although proteins involved in DNA repair may predict HNSCC response to radiotherapy, none has been validated in this context. We examined whether differential expression of double-strand DNA break (DSB) repair proteins in HNSCC, the chief mediators of DNA repair following irradiation, predict for treatment outcomes. EXPERIMENTAL
DESIGN: Archival HNSCC tumor specimens (n = 89) were assembled onto a tissue microarray and stained with antibodies raised against 38 biomarkers. The biomarker set was enriched for proteins involved in DSB repair, in addition to established mechanistic markers of radioresistance. Staining was correlated with treatment response and survival alongside established clinical and pathologic covariates. Results were validated in an independent intramural cohort (n = 34).
RESULTS: Ku80, a key mediator of DSB repair, correlated most closely with clinical outcomes. Ku80 was overexpressed in half of all tumors, and its expression was independent of all other covariates examined. Ku80 overexpression was an independent predictor for both locoregional failure and mortality following radiotherapy (P < 0.01). The predictive power of Ku80 overexpression was confined largely to HPV-negative HNSCC, where it conferred a nine-fold greater risk of death at two years.
CONCLUSIONS: Ku80 overexpression is a common feature of HNSCC, and is a candidate DNA repair-related biomarker for radiation treatment failure and death, particularly in patients with high-risk HPV-negative disease. It is a promising, mechanistically rational biomarker to select individual HPV-negative HNSCC patients for strategies to intensify treatment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21349997      PMCID: PMC3092475          DOI: 10.1158/1078-0432.CCR-10-2641

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  32 in total

1.  Ku autoantigen affects the susceptibility to anticancer drugs.

Authors:  S H Kim; D Kim; J S Han; C S Jeong; B S Chung; C D Kang; G C Li
Journal:  Cancer Res       Date:  1999-08-15       Impact factor: 12.701

2.  Prospective imaging assessment of mortality risk after head-and-neck radiotherapy.

Authors:  Benjamin J Moeller; Vishal Rana; Blake A Cannon; Michelle D Williams; Erich M Sturgis; Lawrence E Ginsberg; Homer A Macapinlac; J Jack Lee; K Kian Ang; K S Clifford Chao; Gregory M Chronowski; Steven J Frank; William H Morrison; David I Rosenthal; Randal S Weber; Adam S Garden; Scott M Lippman; David L Schwartz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-02-18       Impact factor: 7.038

Review 3.  The life and death of DNA-PK.

Authors:  Spencer J Collis; Theodore L DeWeese; Penelope A Jeggo; Antony R Parker
Journal:  Oncogene       Date:  2005-02-03       Impact factor: 9.867

4.  Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial.

Authors:  B Jeremic; Y Shibamoto; B Milicic; N Nikolic; A Dagovic; J Aleksandrovic; Z Vaskovic; L Tadic
Journal:  J Clin Oncol       Date:  2000-04       Impact factor: 44.544

5.  Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data?

Authors:  M S Pepe; M Mori
Journal:  Stat Med       Date:  1993-04-30       Impact factor: 2.373

6.  Comparison of the Radiation Therapy Oncology Group recursive partitioning classification and Union Internationale Contre le Cancer TNM classification for patients with head and neck carcinoma.

Authors:  Xavier León; Ignasi Gich; César Orús; María Del Prado Venegas; Juan Ramón Gras; Miquel Quer
Journal:  Head Neck       Date:  2005-03       Impact factor: 3.147

7.  Recursive partitioning analysis of 2105 patients treated in Radiation Therapy Oncology Group studies of head and neck cancer.

Authors:  J S Cooper; N C Farnan; S O Asbell; M Rotman; V Marcial; K K Fu; W G McKenna; B Emami
Journal:  Cancer       Date:  1996-05-01       Impact factor: 6.860

8.  Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma.

Authors:  Fabrice Denis; Pascal Garaud; Etienne Bardet; Marc Alfonsi; Christian Sire; Thierry Germain; Philippe Bergerot; Beatrix Rhein; Jacques Tortochaux; Gilles Calais
Journal:  J Clin Oncol       Date:  2003-12-02       Impact factor: 44.544

9.  Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression.

Authors:  Christine H Chung; Joel S Parker; Gamze Karaca; Junyuan Wu; William K Funkhouser; Dominic Moore; Dale Butterfoss; Dong Xiang; Adam Zanation; Xiaoying Yin; William W Shockley; Mark C Weissler; Lynn G Dressler; Carol G Shores; Wendell G Yarbrough; Charles M Perou
Journal:  Cancer Cell       Date:  2004-05       Impact factor: 31.743

10.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.

Authors:  Helen E Bryant; Niklas Schultz; Huw D Thomas; Kayan M Parker; Dan Flower; Elena Lopez; Suzanne Kyle; Mark Meuth; Nicola J Curtin; Thomas Helleday
Journal:  Nature       Date:  2005-04-14       Impact factor: 69.504

View more
  40 in total

1.  Developing Predictive or Prognostic Biomarkers for Charged Particle Radiotherapy.

Authors:  Michael D Story; Jing Wang
Journal:  Int J Part Ther       Date:  2018

Review 2.  Opportunities and challenges facing biomarker development for personalized head and neck cancer treatment.

Authors:  Alexandra Lucs; Benjamin Saltman; Christine H Chung; Bettie M Steinberg; David L Schwartz
Journal:  Head Neck       Date:  2012-01-27       Impact factor: 3.147

Review 3.  New challenges in high-energy particle radiobiology.

Authors:  M Durante
Journal:  Br J Radiol       Date:  2014-03       Impact factor: 3.039

Review 4.  Genotypic characteristics of resistant tumors to pre-operative ionizing radiation in rectal cancer.

Authors:  Zeeshan Ramzan; Ammar B Nassri; Sergio Huerta
Journal:  World J Gastrointest Oncol       Date:  2014-07-15

5.  Molecular biomarkers in the decision of treatment of cervical carcinoma patients.

Authors:  A Valenciano; L A Henríquez-Hernández; M Lloret; B Pinar; P C Lara
Journal:  Clin Transl Oncol       Date:  2013-02-22       Impact factor: 3.405

Review 6.  New biological markers in the decision of treatment of head and neck cancer patients.

Authors:  A Valenciano; L A Henríquez-Hernández; M Lloret; B Pinar; P C Lara
Journal:  Clin Transl Oncol       Date:  2014-07-01       Impact factor: 3.405

Review 7.  Personalized radiotherapy: concepts, biomarkers and trial design.

Authors:  A H Ree; K R Redalen
Journal:  Br J Radiol       Date:  2015-05-20       Impact factor: 3.039

8.  PARP Inhibition Enhances Radiotherapy of SMAD4-Deficient Human Head and Neck Squamous Cell Carcinomas in Experimental Models.

Authors:  Ariel L Hernandez; Christian D Young; Li Bian; Kelsey Weigel; Kyle Nolan; Barbara Frederick; Gangwen Han; Guanting He; G Devon Trahan; Michael C Rudolph; Kenneth L Jones; Ayman J Oweida; Sana D Karam; David Raben; Xiao-Jing Wang
Journal:  Clin Cancer Res       Date:  2020-03-05       Impact factor: 12.531

9.  XPF expression correlates with clinical outcome in squamous cell carcinoma of the head and neck.

Authors:  Alec Vaezi; Xiaozhe Wang; Shama Buch; William Gooding; Lin Wang; Raja R Seethala; David T Weaver; Alan D D'Andrea; Athanassios Argiris; Marjorie Romkes; Laura J Niedernhofer; Jennifer R Grandis
Journal:  Clin Cancer Res       Date:  2011-07-07       Impact factor: 12.531

Review 10.  DNA repair dysregulation from cancer driver to therapeutic target.

Authors:  Nicola J Curtin
Journal:  Nat Rev Cancer       Date:  2012-12       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.